The Importance of Biomarkers for Precision Oncology
Biomarker detection and analysis have significantly impacted cancer research, shifting the focus from anatomical classifications to the molecular basis of disease. This has been further aided by liquid biopsy methods, which allow noninvasive interrogation of cancer mutations. These advancements allow researchers to rapidly uncover critical details about tumor progression and predict treatment efficacy.
Precision oncology relies on accurately detecting a wide range of biomarkers, from proteins, circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs). To make meaningful discoveries, you need sensitive tools that detect single nucleotide variants (SNVs), copy number variations (CNVs), insertions/deletions (INDELs), structural variants, measure gene expression levels, and analyze DNA methylation with precision and reliability.
By leveraging our advanced Droplet Digital™ PCR solutions, you can track tumor evolution, advance treatment strategies, and accelerate scientific breakthroughs that improve patient care. With the right technology, you’re not just generating data—you are driving the future of precision medicine.
Did you know?
The National Comprehensive Cancer Network (NCCN) has developed comprehensive guidelines for biomarker testing across more than 50 cancer indications.¹ These evidence-based recommendations play a pivotal role in ensuring patients receive personalized, targeted therapies aligned with their tumor’s distinct molecular profile—significantly enhancing treatment precision and outcomes.
In collaboration with international organizations, these efforts are shaping a global framework for biomarker-driven care, continuously advancing the frontiers of cancer detection, diagnosis, and therapy optimization.
Featured Content
Push the Boundaries of Low-Abundance Biomarker Detection
Detecting low-abundance biomarkers is critical for therapy selection, molecular/minimal residual disease (MRD) tracking, and monitoring recurrence. Yet their trace levels in liquid biopsies and other samples make accurate quantification challenging, requiring advanced tools with exceptional; sensitivity and reproducibility.
While many methods have advanced the field, no single approach fits all needs. Our versatile toolbox of platforms and assays enables ultra-sensitive detection (as low as 0.01%), Formalin-Fixed-Embedded (FFPE) tissue or cell-free DNA (cfDNA) and cost-effective multi-marker detection- empowering you with innovative solutions to overcome your biomarker detection challenges.
QX600™ ddPCR System
Detect and quantify even the rarest nucleic acid events in high background environments with the ultra-high sensitivity, precision, and multiplexing capabilities of ddPCR. This revolutionary technology ensures reproducible results, even from low-yield samples.
ddPLEX ESR1 Mutation Detection Kit
Advance your breast cancer research with the flagship kit designed for the QX600 platform and optimized for FFPE tissue and liquid biopsy samples. It delivers rapid, reliable, and cost-effective insights into ESR1 mutations.
QX200™ ddPCR System
Quantify rare mutations and tumor evolution with ease. The QX200 enables a streamlined and economical workflow while delivering highly robust, accurate results.
ddPCR MSI Kit
Perform multiplexed MSI biomarker research in colorectal and endometrial cancer samples to get same-day results. Optimized for FFPE tissue and plasma, this kit simplifies the analysis process.
ddPCR Multiplex Mutation Screening Kits
Choose from several easy-to-use, highly optimized mutation screening kits. These products deliver consistent results across diverse samples, including FFPE tissue, plasma, and fresh or frozen samples.
Hematology Oncology Assays
Detect critical blood malignancy biomarkers with high sensitivity to drive your MRD research forward, enabling you to uncover valuable insights from even the lowest abundance signals.
Harness the Power of Methylation Detection for Deeper Insights
DNA methylation plays a key role in cancer biology, influencing gene expression and tumor development. With ddPCR and methylation-sensitive restriction enzyme (MSRE) technologies, you can achieve ultra-sensitive, cost-effective methylation detection—unlocking critical epigenetic insights to advance your biomarker research.
Unlock the Secrets of ESR1 with ddPCR
For three decades, researchers have studied ESR1 mutations in breast cancer. Now, ctDNA analysis with ddPCR solutions offers a faster, more precise, and cost-effective workflow. Our ddPLEX ESR1 Mutation Detection Kit simplifies analysis, driving new breakthroughs in your research.
Featured Content
Setting a Global Standard for Biomarker Testing
The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of top cancer centers, has set biomarker testing guidelines for 50+ cancer types. These guidelines help standardize molecular profiling for diagnosis, prognosis, and treatment, ensuring patients receive the most promising therapies.
Other key organizations also shape biomarker testing standards. The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) also provide global perspectives on precision oncology and biomarker driven cancer treatment.
Analyze Liquid Biopsy Samples with Multiplexed Mutation Assays
Achieve ultra-sensitive detection of common mutations like BRAF, NRAS, and TERT with ddPCR technology. Further, plasma-based analysis expands research capabilities when tissue is unavailable, delivering same day results with user-friendly workflows. Learn more about these techniques from this expert webinar.
Featured Content
Ensure Consistency and Reproducibility
Reproducibility is a major cornerstone of effective biomarker testing research. Challenging samples can influence the accuracy of results, particularly in multi-site studies and clinical research settings. ddPCR solutions are indispensable in these scenarios due to its low intra-site coefficient of variation (CV), ensuring ultra-high precision when consistency is critical.
Featured Content
Decentralize Clinical Research Studies
Biomarker detection for large-scale, inter- and intra-site clinical research demands high sensitivity and precision in order to reduce resource burden. Reliable, low-effort workflows must deliver rapid, cost-effective results while maintaining data integrity. By enabling accurate, reproducible analysis from minimal sample input, we help you confidently generate meaningful insights—no matter the scale or location.
QX600™ ddPCR System
Analyze up to 12 biomarkers per sample with advanced multiplexing capabilities, saving time and resources to accelerate your multi-marker analysis.
Multiplexed Mutation Detection Kits
Streamline mutation analysis with optimized kits, delivering efficient, robust, cost-effective results across FFPE tissue, plasma, and fresh frozen samples.
ddPCR Assay Library
Explore our vast library of oncology assays, each meticulously designed for ddPCR platforms to deliver precise, high-sensitivity biomarker detection.
Custom Assay Design Tool
Design custom-tailored assays for the specific mutations you need to analyze. Unlock the full potential of your research with this highly flexible, user-friendly tool.
Expert Designed ddPCR Assays
Streamline your research with expertly developed assays from oncology leaders, providing unmatched accuracy for detecting key biomarkers.
Solutions for Biomarker Analysis
Address sensitivity, throughput, and reliability challenges to accelerate biomarker discovery and validation. Analyze biomarkers across genomic, proteomic, and cellular levels to transform your research and advance personalized treatment research.
Ready to Elevate Your Research?
Featured Content
Featured Resources
-
Image
MSI-H Detection by ddPCR solutions in Endoscopic Ultrasound Fine Needle Biopsy
Enhance MSI-H detection in pancreatic cancer with ddPCR products, enabling precise molecular analysis from endoscopic biopsy samples to improve immunotherapy selection.
-
Image
Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues
Compare advanced molecular assays for MSI detection in endometrial and colorectal cancer, evaluating ddPCR solutions, NGS, and qPCR for sensitivity, speed, and accuracy.
-
Image
Biomarker Workflow Solutions
Explore cutting-edge workflows for genomic and proteomic biomarker detection, accelerating research in oncology, immunology, and precision medicine.
-
Image
Rare Mutation Detection Best Practices Guidelines
Optimize rare mutation detection with validated ddPCR protocols to enhance accuracy and reproducibility for impactful genetic analysis.
-
Image
The Pathway to Accuracy with Droplet Digital PCR (Webinar)
Learn how ddPCR technology is enhancing BCR-ABL1 monitoring for CML in this webinar featuring leading experts in molecular diagnostics.
-
Image
Mutation Detection Multiplexing Using the QX600 Droplet Digital PCR System
Discover how advanced ddPCR multiplexing enables precise detection of cancer mutations, transforming workflows for translational and clinical oncology research.
References
1Treatment by cancer type. (n.d.). NCCN. https://www.nccn.org/guidelines/category_1
Featured Content
Explore Additional Oncology Solutions
CTC Isolation Analysis
Streamline CTC isolation with cutting-edge microfluidics and molecular tools. Enhance reproducibility and accelerate discoveries in liquid biopsy research.
Tumor Profiling
Optimize tumor profiling with advanced molecular tools. Detect rare mutations, analyze gene expression, and uncover biomarkers with confidence and precision.
ctDNA Analysis
Enhance your oncology research with ddPCR for ctDNA analysis. Detect rare mutations, track MRD, and monitor recurrence with unmatched sensitivity and accuracy.
CML Monitoring
Simplify CML monitoring with ddPCR technology. Achieve ultra-sensitive BCR-ABL detection, streamlined workflows, and reproducible results across labs.